Interní Med. 2006; 8(3): 138-141

Optimalizace léčby chronického srdečního selhání ace inhibitory a betablokátory

doc. MUDr. Ivan Málek CSc
Kardiocentrum FN Královské Vinohrady, III. lékařská fakulta Univerzity Karlovy, Praha

ACE inhibitory a betablokátory patří k základním lékům chronického srdečního selhání. ACE inhibitory jsou doporučovány jako léky prvé volby, jsou však důvody k domněnce, že nejde vždy o nejlepší postup. Recentně publikované výsledky studie CIBIS III ukázaly, že zahájení léčby ACE inhibitory nemá žádné výhody proti volbě opačného pořadí léků. Zůstává na uvážení lékaře, aby po posouzení konkrétní klinické situace volil nejlepší variantu. Cílem je vždy léčba kombinovaná, která přináší nemocnému největší prospěch.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek I. Optimalizace léčby chronického srdečního selhání ace inhibitory a betablokátory. Interní Med. 2006;8(3):138-141.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berger R, Strecker K, Hülsmann M. et al.: Experience with ?-blocker therapy in patients with advanced heart failure evaluated for HTx. J Heart Lung Transpl. 2000; 19: 1081-1088. Go to original source... Go to PubMed...
    2. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. LANCET 1999; 353, 9-13. Go to PubMed...
    3. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-1435.
    4. ESC Guidelines. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). The task force for the diagnosis and treatment of CHF of the European Society of Cardiology. Eur Heart J., 2005; 26: 2473-2474. Go to original source...
    5. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489-497. Go to original source... Go to PubMed...
    6. Hjalmarson, Herlitz J, Málek I. et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; 2: 823-827. Go to original source... Go to PubMed...
    7. Hunt SA, et al. ACC/AHA 2005. guideline update for the diagnosis and management of chronic heart failure in the adult. ACC Current Journal Review 2005; 14: 41-45. Go to original source...
    8. Lowes BD, Gill EA, Rodrigue-Larrain J, et al. Carvedilol is associated with a reversal of remodelling in chronic heart failure. Circulation 1996; 94: 1-407.
    9. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure; Metoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001. Go to original source...
    10. McMurray JJV, Östergen J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added Trial. Lancet 2003; 362: 767-771. Go to original source... Go to PubMed...
    11. Otterstad JE, Ford I. The effects of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002; 4: 495-499. Go to original source... Go to PubMed...
    12. Packer M, Bristow MR, Cohn JN, et al. for the US carvedilol heart failure study group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349. Go to original source... Go to PubMed...
    13. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344: 1651-1658. Go to original source... Go to PubMed...
    14. Remme WJ. The Carvedilol and ACE-inhibitor Remodelling Mild heart failure Evaluation trial (CARMEN) - rationale and design. Cardiovascular Drugs and Therapy 2001; 15: 69-77. Go to original source... Go to PubMed...
    15. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 292-302. Go to original source... Go to PubMed...
    16. Špinar J, Hradec J, Málek I, Toman J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání. Cor Vasa 2001; 43: K123-137.
    17. Willenheimer R, Erdmann E, Follath F, et al. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Eur J Heart Failure 2004; 6: 493-500. Go to original source... Go to PubMed...
    18. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators. N Engl J Med. 2000; 342: 145-153. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.